TargetBeta
NT5E
5'-nucleotidase ecto · also CD73, eN, eNT, CALJA · CD molecules
3 programs in company-led studies act on NT5E, from 3 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| oleclumab | AstraZeneca | – | phase 3 | 84 running | – | a judged reading |
| quemliclustatrule | Arcus Biosciences | inhibitor | phase 3 | 72 running | – | NCIt |
| uliledlimabrule | TJ Biopharma | – | phase 3 | 41 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Adenocarcinoma Of Esophagus, 1 program
- Carcinoma, 1 program
- Colonic Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
- Ovarian Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 8, 2027oleclumab · AstraZeneca · phase 3 · NCT05221840
- Dec 2027quemliclustat · Arcus Biosciences · phase 3 · NCT05676931
- Aug 5, 2028uliledlimab · TJ Biopharma · phase 3 · NCT06984588
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.